Form 4: Myriad Genetics Director S. Louise Phanstiel Acquires Over 49,000 Shares Through RSU Grant

Myriad Genetics Inc. Director S. Louise Phanstiel reported the acquisition of 49,796 shares of common stock through a restricted stock unit grant on June 5, 2025, increasing her total beneficial ownership to 177,444 shares.

Summary

• S. Louise Phanstiel, a Director of Myriad Genetics Inc. (MYGN), acquired 49,796 shares of common stock.
• The transaction occurred on June 5, 2025.
• These shares were acquired at a price of $0, indicating they were part of a restricted stock unit (RSU) grant.
• The RSUs were granted under Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended.
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• Vesting of these RSUs will occur upon the earlier of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following such grant.
• Following this transaction, S. Louise Phanstiel's total beneficial ownership of Myriad Genetics common stock is 177,444 shares.

Sentiment

Score: 7

Explanation: The filing reports a standard equity grant to a director, which is generally a positive sign of alignment between management and shareholder interests, but it does not contain new operational or financial performance data to significantly alter sentiment.

Positives

• The acquisition of 49,796 shares by a director, S. Louise Phanstiel, through an RSU grant indicates continued alignment of management's interests with shareholders.
• The grant is part of the company's established 2017 Employee, Director and Consultant Equity Incentive Plan, suggesting a structured approach to executive compensation and retention.

Risks

• The value of the acquired shares (RSUs) is subject to the future performance of Myriad Genetics' stock price until vesting.
• Future changes in the company's equity incentive plan or RSU terms could impact the value or timing of share receipt.

Future Outlook

The vesting schedule for the RSUs indicates that the shares will become fully owned by the director upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant, aligning the director's long-term interests with the company's performance.

Industry Context

This is a standard insider transaction (equity grant) common across publicly traded companies, particularly in the biotechnology and diagnostics sector like Myriad Genetics, to incentivize and retain key personnel. It reflects a common practice of using equity compensation to align director interests with shareholder value.

Comparison to Industry Standards

• Equity grants, specifically Restricted Stock Units (RSUs) with vesting schedules, are a widely accepted form of non-cash compensation for directors and executives in the biotechnology and healthcare industries.
• Companies such as Illumina (ILMN), Exact Sciences (EXAS), and Guardant Health (GH) also utilize similar equity incentive plans to compensate their leadership, aligning their interests with long-term company performance and shareholder returns.
• The specific number of shares granted would typically be benchmarked against peer companies' compensation practices for directors of similar tenure and responsibility within the sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to equity ownership.
• Employees/Directors: Demonstrates the company's ongoing use of its equity incentive plan for compensation.

Next Steps

• The acquired RSUs will vest upon the earlier of the first anniversary of the grant date (June 5, 2026) or the date of the next annual meeting of stockholders following the grant.

Key Dates

Recommendation

Keywords

Myriad Genetics, MYGN, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Equity Incentive Plan, Beneficial Ownership